| Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside |
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer. |
benzinga.com |
2025-05-07 20:45:18 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study |
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 |
We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase. |
seekingalpha.com |
2025-04-16 16:09:11 |
Czytaj oryginał (ang.) |
| SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. |
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024. |
globenewswire.com |
2025-03-06 09:40:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 |
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence Epilepsy and DEE could have data released by 2026, potentially establishing it as a best-in-class 5-HT2C receptor agonist. The company has a $35 million private placement, extending its cash runway beyond 2026 and supporting its pipeline, including drugs for depression, PTSD, and anxiety. |
seekingalpha.com |
2025-01-26 08:32:26 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer |
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an advisory capacity. |
globenewswire.com |
2025-01-07 08:50:00 |
Czytaj oryginał (ang.) |
| CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER |
WESTON, Fla. , Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. |
prnewswire.com |
2024-12-09 09:33:00 |
Czytaj oryginał (ang.) |
| Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month |
The reason for the stock's rapid ascent is a mystery. |
fool.com |
2024-11-13 14:59:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). |
prnewswire.com |
2024-11-06 19:21:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement |
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”). |
globenewswire.com |
2024-11-04 16:41:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential |
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform targets serotonin regulation, aiming to create selective therapies with fewer side effects. DRUG's recent $35 million private placement funds Phase 2 trials, enhancing its financial outlook and potential for significant revenue if BMB-101 is successful. |
seekingalpha.com |
2024-10-30 03:07:00 |
Czytaj oryginał (ang.) |
| PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update |
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial. |
businesswire.com |
2024-10-28 10:21:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data |
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). |
globenewswire.com |
2024-10-21 12:30:00 |
Czytaj oryginał (ang.) |
| Monster insider trading alert for this penny stock that rallied $3,700% in a week |
This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed to historic levels, and it seems several investors have profited significantly from this momentum. |
finbold.com |
2024-10-19 17:11:35 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement |
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES |
globenewswire.com |
2024-10-18 10:50:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models |
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program. Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls. |
globenewswire.com |
2024-10-16 14:45:00 |
Czytaj oryginał (ang.) |
| Why did this penny stock skyrocket 1,500% in a day |
When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a meteoric rise, with minimal fundamental factors supporting this momentum. |
finbold.com |
2024-10-16 13:05:33 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences Stock Surges Almost 1,500% |
Bright Minds Biosciences NASDAQ: DRUG, a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading under 1 million shares daily, the stock saw over 100 million shares change hands without any direct news. |
marketbeat.com |
2024-10-16 12:46:16 |
Czytaj oryginał (ang.) |
| Canadian psychedelics company Bright Minds shares rise 1,446% in one day |
Yesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of psychedelics, saw its shares rocket by a frankly psychedelic-looking 1,445.8% to $38.49 from $2.50 at the start of the day. At the request of the Canadian Investment Regulatory Organization (CIRO), Bright Minds confirmed that management "is unaware of any material changes in the company's operations that would account for the recent increase in market activity". |
proactiveinvestors.co.uk |
2024-10-16 12:04:18 |
Czytaj oryginał (ang.) |
| Bright Minds is Unaware of Any Material Changes |
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity. About Bright Minds Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. |
newsfilecorp.com |
2024-10-16 01:09:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events |
Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences: Neuroscience 2024 annual meeting, organized by the Society for Neuroscience (SfN), will take place in Chicago, October 5–9. Therapeutic Development at NINDS Chicago, October 7, 2024. |
globenewswire.com |
2024-10-03 13:00:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th |
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th. The event will feature Epilepsy KOLs to discuss the unmet needs for epilepsy treatment. |
globenewswire.com |
2024-09-19 14:00:00 |
Czytaj oryginał (ang.) |
| Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy |
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at 10:00 ET NEW YORK , Sept. |
prnewswire.com |
2024-09-12 12:00:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) |
FDA confirms the favorable benefit-risk profile of WAKIX Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the next five years PLYMOUTH MEETING, Pa. , June 25, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. |
prnewswire.com |
2024-06-25 12:05:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY |
PLYMOUTH MEETING, Pa. , June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy. |
prnewswire.com |
2024-06-24 11:00:00 |
Czytaj oryginał (ang.) |
| ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY |
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. |
globenewswire.com |
2024-06-11 12:10:00 |
Czytaj oryginał (ang.) |